Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

Meredith Milstein, Leonid Lecca, Charles Peloquin, Denis Mitchison, Kwonjune Seung, Marcello Pagano, David Coleman, Elna Osso, Julia Coit, Dante Elmo Vargas Vasquez, Epifanio Sanchez Garavito, Roger Calderon, Carmen Contreras, Geraint Davies, Carole D Mitnick, Meredith Milstein, Leonid Lecca, Charles Peloquin, Denis Mitchison, Kwonjune Seung, Marcello Pagano, David Coleman, Elna Osso, Julia Coit, Dante Elmo Vargas Vasquez, Epifanio Sanchez Garavito, Roger Calderon, Carmen Contreras, Geraint Davies, Carole D Mitnick

Abstract

Background: Evidence has existed for decades that higher doses of rifampin may be more effective, but potentially more toxic, than standard doses used in tuberculosis treatment. Whether increased doses of rifampin could safely shorten treatment remains an open question.

Methods/design: The HIRIF study is a phase II randomized trial comparing rifampin doses of 20 and 15 mg/kg/day to the standard 10 mg/kg/day for the first 2 months of tuberculosis treatment. All participants receive standard doses of companion drugs and a standard continuation-phase treatment (4 months, 2 drugs). They are followed for 6 months post treatment. Study participants are adults with newly diagnosed, previously untreated, smear positive (≥2+) pulmonary tuberculosis. The primary outcome is rifampin area under the plasma concentration-time curve (AUC0-24) after at least 14 days of study treatment/minimum inhibitory concentration. 180 randomized participants affords 90 % statistical power to detect a difference of at least 14 mcg/mL*hr between the 20 mg/kg group and the 10 mg/kg group, assuming a loss to follow-up of up to 17 %.

Discussion: Extant evidence suggests the potential for increased doses of rifampin to shorten tuberculosis treatment duration. Early studies that explored this potential using intermittent, higher dosing were derailed by toxicity. Given the continued large, global burden of tuberculosis with nearly 10 million new cases annually, shortened regimens with existing drugs would offer an important advantage to patients and health systems.

Trial registration: This trial was registered with clinicaltrials.gov (registration number: NCT01408914 ) on 2 August 2011.

Keywords: Pharmacokinetics; Randomized trial; Rifampi(ci)n; Treatment shortening; Tuberculosis.

Figures

Fig. 1
Fig. 1
Flow of 12-month study participation

References

    1. WHO. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health Organization; 2015.
    1. TB Alliance: Global Alliance for TB Drug Development . New TB Regimens: What Countries Want. 2009.
    1. Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. Int J Tuberc Lung Dis. 2013;17(5):590–6. doi: 10.5588/ijtld.12.0776.
    1. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63. doi: 10.1164/rccm.200904-0536OC.
    1. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738–47. doi: 10.1016/S0140-6736(14)62002-X.
    1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87. doi: 10.1056/NEJMoa1407426.
    1. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608. doi: 10.1056/NEJMoa1314210.
    1. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98. doi: 10.1056/NEJMoa1315817.
    1. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(3):331–8. doi: 10.1164/rccm.200603-360OC.
    1. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180(3):273–80. doi: 10.1164/rccm.200901-0078OC.
    1. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206(7):1030–40. doi: 10.1093/infdis/jis461.
    1. Peloquin C. What is the ‘right’ dose of rifampin? Int J Tuberc Lung Dis. 2003;7(1):3–5.
    1. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4(9):796–806.
    1. Mitchison DA. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med. 2004;25(3):307–15. doi: 10.1055/s-2004-829503.
    1. Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis. 2008;88(Suppl 1):S65–74. doi: 10.1016/S1472-9792(08)70037-4.
    1. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009;10(3):381–401. doi: 10.1517/14656560802694564.
    1. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R. Plemper van Balen G, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52(9):e194–9.
    1. Rifampicin. Tubercle. 1969;50(3):318–20. doi:10.1016/0041-3879(69)90058-0.
    1. Peloquin C, Vernon A. Antimycobacterial Agents: Rifamycins for Mycobacterial Infections. In: Yu V, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Pittsburgh: ESun Technologies; 2005. pp. 383–402.
    1. Dickinson JM, Jackett PS, Mitchison DA. The effect of pulsed exposures to rifampin on the uptake of uridine- 14 C by Mycobacterium tuberculosis. Am Rev Respir Dis. 1972;105(4):519–27.
    1. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–24. doi: 10.1128/AAC.47.7.2118-2124.2003.
    1. Grumbach F. Experimental “in vivo” studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin. Tubercle. 1969;50(Suppl):12–21.
    1. Kradolfer F. Rifampicin, isoniazid, ethambutol, ethionamide, and streptomycin in murine tuberculosis: comparative chemotherapeutic studies. Antibiotica et chemotherapia Fortschritte Advances Progres. 1970;16:352–60.
    1. Verbist L. Rifampicin activity “in vitro” and in established tuberculosis in mice. Acta Tuberc Pneumol Belg. 1969;60(3):397–412.
    1. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004;2(4):289–300. doi: 10.1038/nrmicro862.
    1. Decroix G, Kreis B, Sors C, Birembaum J, Le Lirzin M, Canetti G. Comparison between regimes of rifampicin-isoniazid administered daily and administered twice a week (initial results of a comparative study conducted in 4 medical services of the Parisian region). Rev Tuberc Pneumol. 1969;33(6):751–68.
    1. Nitti V. Antituberculosis activity of rifampin. Report of studies performed and in progress (1966–1971) Chest. 1972;61(6):589–98. doi: 10.1378/chest.61.6_Supplement.589.
    1. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983;5(Suppl 3):S428–32. doi: 10.1093/clinids/5.Supplement_3.S428.
    1. Poole G, Stradling P, Worlledge S. Potentially serious side-effects of high-dose twice-weekly rifampicin. Postgrad Med J. 1971;47(553):727–47. doi: 10.1136/pgmj.47.553.742.
    1. Aquinas M, Allan WG, Horsfall PA, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71. doi: 10.1136/bmj.1.5803.765.
    1. A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report. Tubercle. 1976;57(2):105–13.
    1. Girling DJ. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother. 1977;3(2):115–32. doi: 10.1093/jac/3.2.115.
    1. Dhar S, Kaur I, Sharma VK, Kumar B. “Flu” syndrome due to rifampin; experience with four cases. Int J Lepr Other Mycobact Dis. 1995;63(1):92–4.
    1. Reichler MR, Allphin AA, Breiman RF, Schreiber JR, Arnold JE, McDougal LK, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis. 1992;166(6):1346–53. doi: 10.1093/infdis/166.6.1346.
    1. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39(2):235–40. doi: 10.1093/jac/39.2.235.
    1. Baty V, Hoen B, Schuhmacher H, Amiel C, Reyrolle M, Garin H, et al. Legionella jordanis pneumonia unresponsive to fluoroquinolones in a non-immunocompromised host. Scand J Infect Dis. 1997;29(3):319–20. doi: 10.3109/00365549709019054.
    1. Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM. 2000;93(11):733–7. doi: 10.1093/qjmed/93.11.733.
    1. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–65. doi: 10.1164/rccm.201407-1264OC.
    1. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170–7. doi: 10.1128/AAC.50.4.1170-1177.2006.
    1. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med. 2005;172(1):128–35. doi: 10.1164/rccm.200411-1557OC.
    1. Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, et al. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2006;50(2):822–3. doi: 10.1128/AAC.50.2.822-823.2006.
    1. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994–6. doi: 10.1128/AAC.01474-06.
    1. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61(5):544–53. doi: 10.1016/S0009-9236(97)90134-X.
    1. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99(2):465–71. doi: 10.1378/chest.99.2.465.
    1. Rifapentine (Priftin) [package insert]. sanofi-aventis U.S. LLC, Bridgewater, NJ 08807. Revised December 2014. .
    1. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013;57(8):3614–9. doi: 10.1128/AAC.02468-12.
    1. Davies GR, Khoo SH, Aarons LJ. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J Antimicrob Chemother. 2006;58(3):594–600. doi: 10.1093/jac/dkl272.
    1. Cochrane AL. Archie Cochrane in his own words. Selections arranged from his 1972 introduction to “Effectiveness and Efficiency: Random Reflections on the Health Services” 1972. Control Clin Trials. 1989;10(4):428–33. doi: 10.1016/0197-2456(89)90008-1.
    1. Global Drug Facility . Procurement and supply. Stop TB Partnership. 2015.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner